MRES Quick summary to get up to speed…
*CEO with skin in the game and a long record of success in various venues.It’s important to do your own homework . Unfortunately, many will miss this since its labeled a scam by many. I am providing this due diligence so you can see some of Jeff Robinson’s accurate background along with the many businessmen he’s involved with.
PRTG $10.13 with Nasdaq up-list from pennies. PRTG spun out BHVN to shareholders and was recently bought out by Pfizer for over $144.00 a share…
More tidbits…
Pfizer Buys Biohaven In A $12 Billion Deal That ‘Couldn’t Have Come At A Better Time’
https://finance.yahoo.com/m/a73df6be-b246-3daa-b611-e7e1855c3352/pfizer-buys-biohaven-in-a-12.html
PRTG was originally founded by the CEO of WUHN now MRES CEO and his brothers. It was a a pink sheet penny stock and both PRTG and BHVN were added to the big board.
The stock had over $450,000.00 of dollar volume on the news and closed up and a horrible market. These Biotechs have a mind of their own and are driven by approvals along with different Phases of their drug development. They can perform well in any market. PRTG recently had a price target of $32.00. You can see that below.
About us – Portage BioTech, LLC.
https://www.portagebiotech.com/
Important to take note of this previous placement at $23.00 a share:
Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares
Westport, Connecticut–(Newsfile Corp. – June 24, 2021) – Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that it has priced its previously announced underwritten public offering of 1,000,000 ordinary shares. The public offering price of each ordinary share is $23.00.
Major/Institutional holders..
Portage Biotech Inc. (PRTG) Stock Major Holders – Yahoo Finance
Yahoo Finance https://finance.yahoo.com/quote/PRTG/holders?p=PRTG
HC Wainwright & Co. Initiates Coverage On Portage Biotech with Buy Rating, Announces Price Target of $32 |Benzinga]
https://www.benzinga.com/news/22/03/26013754/hc-wainwright-co-initiates-coverage-on-portage-biotech-with-buy-rating-announces-price-target-of-32
Mar 2022 HC Wainwright & Co. Initiates Coverage On Buy
Sep 2021 Oppenheimer Initiates Coverage On Outperform
Sep 2021 B. Riley Securities Initiates Coverage On Buy
Here is one of Jeff’s brothers Terrence and the history with PRTG. You will recognize some other names in there like Dr Bailey who had numerous interviews with WUHN and CEO Jeff Robinson. Search Jim Mellon and see who he is.
(4) Terence Robinson | LinkedIn
Look at the dividend PRTG paid to shareholders below.
Co-Founder
Co-Founder
Portage Biotech Inc
Portage Biotech Inc
Jun 2013 – Present · 9 yrs
Jun 2013 – Present · 9 yrs
Connecticut, United States
Connecticut, United States
Co-founded Portage Biotech in July/2013.Portage(PRTG/NASDAQ) became public as the result of a merger between Bontan Corporation a public entity and Portage, a London/England-based private entity. The controlling shareholders of Portage are Dr.Greg Bailey ( co-founder of Medivation Inc-since taken over by Pfizer for $14 B ) and Jim Mellon, a London-based investor and financier. Portage invested an initial $3 M into a Yale University-based biotech company called Biohaven. Biohaven Pharmaceutical (BHVN) IPO’d in May/2017 on the NYSE and has a current market cap of $8 Billion( $122/share). Portage paid a stock dividend in Biohaven shares (01/18) to its shareholders totaling 6 million shares ( today’s value >$730 M ). Portage is now focused on new drug development for cancer treatments and is listed on NASDAQ under the symbol PRTG
Jim Mellon…
Jim Mellon – Wikipedia
https://en.wikipedia.org/wiki/Jim_Mellon
He also holds non-executive directorships at Condor Gold PLC, Bradda Head Limited (formerly Life Science Developments) and Portage Biotech Inc.
Juvenescence, a biotech company, was founded by Mellon and four others, Greg Bailey,
This M2Bio entity was moved from WUHN to MRES
*Numerous streams of revenue potential.
*Recent spin out of Drug Discovery company.
Wuhan General Group Launches Mental Illness Drug Discovery Company Neurai Life Sciences
https://feeds.issuerdirect.com/news-release.html?newsid=6851533307229560
*CBD line already in 100 stores ,
https://www.otcmarkets.com/stock/WUHN/news/Medspresso-and-Liviana-Carried-by-100-Independent-South-African-Retailers?id=349537
*Exceptional product line includes CBD infused coffees, teas, medicinal mushrooms, olive oils, balms, cosmetics and more.
https://m2bio.co/brands_and_products/
*Psilocybin division … with Tremendous Science and Research in the sector. They have 3 published papers.
https://m2bio.co/science-research/
*Hemp & Mycelium Division…
Sustainable Packaging
https://m2bio.co/wp-content/uploads/2021/08/Hemp-Plastics.pdf
*Cannabis Manufacturing… MediGrow Africa – Tsime Pharmaceuticals
Acquisition to cultivate, extract and process cannabis in Lesotho – licensed for 10 years.
Look at this operation. https://www.medigrowafrica.com/about-us
The Founder – Willem Daniel Jonker
The founder of Medigrow Africa is a chartered Accountant (South Africa) by training. He was a senior partner at Allan Gray (www.allangray.co.za), the largest independent investment manager in South Africa, until 1993. Thereafter he moved into the field of private equity, arranging funding for companies such as Medigrow Africa. linkedin.com/in/willem-jonker-9271a91
Willem D Jonker CFO
https://feeds.issuerdirect.com/news-release.html?newsid=7261780883987446
The company is equally committed to value creation for local communities and has recently received an endorsement from the Lesotho government to develop blockchain projects that support these endeavours.
In its first phases, a seed-to-sale provenance tool for CBD and related products enables M2Bio and the Kingdom of Lesotho to bring trusted bioceutical to the global market. That said, the Research Group has aspirations that are far more wide-reaching.
The new division is headed up by:
Dr. Stewart Southey, a senior partner at Catena, received his MBBCh from The University of the Witwatersrand and completed his postgraduate Anesthesiology training in the UK where he was awarded Fellowship of the Royal College of Anesthetists. Although still practicing as a part time clinician, his passion for innovation in healthcare led him to graduate with an MBA and subsequently an MSc (cum laude) in Digital Currencies and Blockchain. Much of his work focuses on the use of blockchain technology in healthcare.
Dr. Mehran Zarrebini, a senior partner at Catena, is a Chemical Engineer by training, with a PhD in Chemical Engineering from the University of Cambridge, UK. Mehran runs the largest rubber tire recycling company in Africa (based in Kwa-Zulu Natal), and is a global leader in the Circular Economy arena. He has an MBA (cum laude) from the University of Stellenbosch Business School and graduated alongside Dr Southey with an MSc in Digital Currencies and Blockchain.
*Created a new division for Ketamine IV & Personalized Supercharged Vitamin IV Drip
https://feeds.issuerdirect.com/news-release.html?newsid=8840965826654119
There is much more and I suggest you go through all of it..
https://m2bio.co/publications/
The Videos…
https://www.youtube.com/channel/UCOir-dW7tmY7RGKXlUl5esQ/videos